Cargando…

Network-guided prediction of aromatase inhibitor response in breast cancer

Prediction of response to specific cancer treatments is complicated by significant heterogeneity between tumors in terms of mutational profiles, gene expression, and clinical measures. Here we focus on the response of Estrogen Receptor (ER)+ post-menopausal breast cancer tumors to aromatase inhibito...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ruffalo, Matthew, Thomas, Roby, Chen, Jian, Lee, Adrian V., Oesterreich, Steffi, Bar-Joseph, Ziv
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6386390/ https://www.ncbi.nlm.nih.gov/pubmed/30742607 http://dx.doi.org/10.1371/journal.pcbi.1006730

Ejemplares similares

Using single cell atlas data to reconstruct regulatory networks
por: Song, Qi, et al.
Publicado: (2023)

Reconstructing cancer drug response networks using multitask learning
por: Ruffalo, Matthew, et al.
Publicado: (2017)

Protein interaction disruption in cancer
por: Ruffalo, Matthew, et al.
Publicado: (2019)

Precision Medicine in Hormone Receptor-Positive Breast Cancer
por: Nasrazadani, Azadeh, et al.
Publicado: (2018)

A web server for comparative analysis of single-cell RNA-seq data
por: Alavi, Amir, et al.
Publicado: (2018)

Aromatase inhibitor-induced modulation of breast density: clinical and genetic effects
por: Henry, N L, et al.
Publicado: (2013)

Role of aromatase inhibitors in breast cancer
por: Carpenter, R, et al.
Publicado: (2005)

Molecular response to aromatase inhibitor treatment in primary breast cancer
por: Mackay, Alan, et al.
Publicado: (2007)

Antitumor activity of Z-endoxifen in aromatase inhibitor-sensitive and aromatase inhibitor-resistant estrogen receptor-positive breast cancer
por: Jayaraman, Swaathi, et al.
Publicado: (2020)

Bone Safety Profile of Steroidal Aromatase Inhibitor in Comparison to Nonsteroidal Aromatase Inhibitors in Postmenopausal Women with Breast Cancer: A Network Meta-Analysis
por: Chen, Shanshan, et al.
Publicado: (2022)

Expression of Estrogen-Related Gene Markers in Breast Cancer Tissue Predicts Aromatase Inhibitor Responsiveness
por: Moy, Irene, et al.
Publicado: (2013)

Aromatase inhibitor strategies in metastatic breast cancer
por: McArthur, Heather L, et al.
Publicado: (2010)

Clinical utilities of aromatase inhibitors in breast cancer
por: Chumsri, Saranya
Publicado: (2015)

CINS: Cell Interaction Network inference from Single cell expression data
por: Yuan, Ye, et al.
Publicado: (2022)

Sequencing of aromatase inhibitors
por: Bertelli, G
Publicado: (2005)

Aromatase inhibitors in advanced breast cancer: there are efficacy differences
por: Bhatnagar, A S
Publicado: (2005)

Evolution of aromatase inhibitors as an endocrine treatment for breast cancer
por: Miller, WR
Publicado: (2006)

A Polymorphism at the 3′-UTR Region of the Aromatase Gene Is Associated with the Efficacy of the Aromatase Inhibitor, Anastrozole, in Metastatic Breast Carcinoma
por: Liu, Lei, et al.
Publicado: (2013)

Pseudoprogression After Palbociclib with Aromatase Inhibitors Treatment in Metastatic Breast Cancer
por: Huang, Weiwei, et al.
Publicado: (2020)

Aromatase and Dual Aromatase-Steroid Sulfatase Inhibitors from the Letrozole and Vorozole Templates
por: Wood, Paul M, et al.
Publicado: (2011)

Joint pain severity predicts premature discontinuation of aromatase inhibitors in breast cancer survivors
por: Chim, Kannie, et al.
Publicado: (2013)

Estradiol as a Targeted, Late-Line Therapy in Metastatic Breast Cancer with Estrogen Receptor Amplification
por: Kota, Karthik, et al.
Publicado: (2017)

26th Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, USA, 3–6 December 2003: update on preclinical and translational research
por: Lee, Adrian V, et al.
Publicado: (2004)

Obesity and Risk of Recurrence in Patients With Breast Cancer Treated With Aromatase Inhibitors
por: Harborg, Sixten, et al.
Publicado: (2023)

Salivary Estrogens Androgens and Aromatase Inhibitors by LC-MS/MS in Breast Cancer Patients Treated With Testosterone Pellets Combined With Aromatase Inhibitors
por: Zava, David T, et al.
Publicado: (2021)

Long-term safety of aromatase inhibitors in the treatment of breast cancer
por: Nabholtz, Jean-Marc A
Publicado: (2008)

Update on the use of aromatase inhibitors in early-stage breast cancer
por: Kesisis, Georgios, et al.
Publicado: (2009)

Characterising an aromatase inhibitor resistant breast cancer cell line
por: Harris, E, et al.
Publicado: (2012)

Effectiveness of aromatase inhibitors and tamoxifen in reducing subsequent breast cancer
por: Haque, Reina, et al.
Publicado: (2012)

Bone Health History in Breast Cancer Patients on Aromatase Inhibitors
por: Kwan, Marilyn L., et al.
Publicado: (2014)

Acquired resistance to everolimus in aromatase inhibitor-resistant breast cancer
por: Kimura, Mariko, et al.
Publicado: (2018)

Effects of Acupuncture on Breast Cancer Patients Taking Aromatase Inhibitors
por: Qi, Qing-ling, et al.
Publicado: (2022)

The genomic landscape associated with resistance to aromatase inhibitors in breast cancer
por: Sadasivam, Kirithika, et al.
Publicado: (2023)

Simultaneous Quantification of Aromatase Inhibitors and Estrogens in Postmenopausal Breast Cancer Patients
por: Bertelsen, Bjørn-Erik, et al.
Publicado: (2021)

Bone loss and the aromatase inhibitors
por: Lester, J, et al.
Publicado: (2005)

Aromatase inhibitors in male sex
por: Singh, Santosh Kumar
Publicado: (2013)

Aromatase inhibitors in the treatment of endometriosis
por: Słopień, Radosław, et al.
Publicado: (2016)

Molecular Docking of Aromatase Inhibitors
por: Suvannang, Naravut, et al.
Publicado: (2011)

Aromatase Inhibitors in Erectile Dysfunction
por: Singh, Santosh
Publicado: (2021)

Pharmacogenomics of aromatase inhibitors in postmenopausal breast cancer and additional mechanisms of anastrozole action
por: Cairns, Junmei, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_f7ind2gej40s4uuhnhm7k0qccl